2 news items
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
COCP
13 May 24
study with our novel broad-spectrum oral PB2 inhibitor CC-42344 for pandemic and seasonal influenza A, we expect to report topline results
Cocrystal Pharma Receives Pre-IND Responses From The FDA On Oral CC-42344 For Treating Influenza A
COCP
19 Mar 24
-42344 as a potential oral treatment for pandemic and seasonal influenza A. A Pre-IND review provides the opportunity to obtain FDA guidance
- Prev
- 1
- Next